Advertisement

CNS Drugs

, Volume 22, Issue 2, pp 123–138 | Cite as

Pathological Gambling

An Update on Neuropathophysiology and Pharmacotherapy
  • Iulian Iancu
  • Katherine Lowengrub
  • Yael Dembinsky
  • Moshe Kotler
  • Pinhas N. Dannon
Review Article

Abstract

Neurobiological research has shown the potential involvement of serotonergic, dopaminergic and opioid dysfunction in the pathophysiology of pathological gambling. In this review, we present current theories of the neuropathology of pathological gambling, paying particular attention to the role of the neural circuitry underlying motivation, reward, decision-making and impulsivity. This review also presents a literature review of current pharmacological treatment strategies for pathological gambling, such as SSRIs, opioid receptor antagonists, anti-addiction drugs and mood stabilizers, and also discusses the role of nonpharmacological interventions.

A hypothetical model of the clinical subtypes of pathological gambling is presented, e.g. the impulsive subtype, the obsessive-compulsive subtype and the addictive subtype. This model attempts to integrate current knowledge in the field of pathological gambling regarding neuropathology, psychiatric co-morbidity, family history, genetics, course of illness, gender and response to pharmacological treatment. Finally, it is proposed that the existence of possible clinical subtypes of pathological gambling may provide a potential framework for matching the various subtypes with specific pharmacotherapies.

Keywords

Nucleus Accumbens Bupropion Naltrexone Pathological Gambling Gambling Behaviour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Petry NM, Armentano C. Prevalence, assessment, and treatment of pathological gambling: a review. Psychiatr Serv 1999; 50(8): 1021–7PubMedGoogle Scholar
  2. 2.
    Shaffer HJ, Hall MN, Van der Bilt J. Estimating the prevalence of disorder gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89: 1369–76PubMedCrossRefGoogle Scholar
  3. 3.
    Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am 2000; 23(3): 629–42PubMedCrossRefGoogle Scholar
  4. 4.
    Dell’Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemol Ment Health 2005; 1: 21CrossRefGoogle Scholar
  5. 5.
    Dell’Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr 2005; 10(8): 619–21PubMedGoogle Scholar
  6. 6.
    Ibanez A, Blanco C, Donahue E, et al. Psychiatric comorbidity in pathological gamblers seeking treatment. Am J Psychiatry 2001; 158(10): 1733–5PubMedCrossRefGoogle Scholar
  7. 7.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association Inc., 1994Google Scholar
  8. 8.
    The ICD-10 classification of mental and behavioral disorders. Geneva: World Health Organization, 1992Google Scholar
  9. 9.
    Shah KR, Eisen SA, Xian H, et al. Genetic studies of pathological gambling: a review of methodology and analyses of data from the Vietnam era twin registry. J Gambl Stud 2005; 21(2): 179–203PubMedCrossRefGoogle Scholar
  10. 10.
    Black DW, Monahan PO, Temkit M, et al. A family study of pathological gambling. Psychiatry Res 2006; 141(3): 295–303PubMedCrossRefGoogle Scholar
  11. 11.
    Steel Z, Blaszczynski A. Impulsivity, personality disorders and pathological gambling severity. Addiction 1998; 93(6): 895–905PubMedCrossRefGoogle Scholar
  12. 12.
    Scherrer JF, Xian H, Shah KR, et al. Effect of genes, environment, and lifetime co-occurring disorders on health-related quality of life in problem and pathological gamblers. Arch Gen Psychiatry 2005; 62(6): 677–83PubMedCrossRefGoogle Scholar
  13. 13.
    Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry Suppl 1998; 35: 7–12PubMedGoogle Scholar
  14. 14.
    Blaszczynski A. Pathological gambling and obsessive-compulsive spectrum disorders. Psychol Rep 1999; 84: 107–13PubMedCrossRefGoogle Scholar
  15. 15.
    Frost RO, Meagher BM, Riskind JH. Obsessive-compulsive features in pathological lottery and scratch-ticket gamblers. J Gambl Stud 2001; 17(1): 5–19PubMedCrossRefGoogle Scholar
  16. 16.
    Tamminga CA, Nestler EJ. Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 2006; 163(2): 180–1PubMedCrossRefGoogle Scholar
  17. 17.
    Petry NM. Should thescope of addictive behaviors be broadened to include pathological gambling? Addiction 2006; 101Suppl. 1: 152–60PubMedCrossRefGoogle Scholar
  18. 18.
    Nutt DJ. Addiction: brain mechanisms and their treatment implications. Lancet 1996; 347(8993): 31–6PubMedCrossRefGoogle Scholar
  19. 19.
    Spinella M. Evolutionary mismatch, neural reward circuits, and pathological gambling. Int J Neurosci 2003; 113(4): 503–12PubMedCrossRefGoogle Scholar
  20. 20.
    Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002; 13(5–6): 355–66PubMedCrossRefGoogle Scholar
  21. 21.
    Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8(2): 147–8PubMedCrossRefGoogle Scholar
  22. 22.
    Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162(8): 1403–13PubMedCrossRefGoogle Scholar
  23. 23.
    Chambers RA, Potenza MN. Neurodevelopment, impulsivity, and adolescent gambling. J Gambl Stud 2003; 19(1): 53–84PubMedCrossRefGoogle Scholar
  24. 24.
    Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191(3): 391–431CrossRefGoogle Scholar
  25. 25.
    Goldstein RZ, Volkow ND. Drug addiction and its underlying neurological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642–52PubMedCrossRefGoogle Scholar
  26. 26.
    Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999; 146(4): 373–90CrossRefGoogle Scholar
  27. 27.
    Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60(8): 818–36CrossRefGoogle Scholar
  28. 28.
    Bechara A. Neurobiology of decision-making: risk and reward. Semin Clin Neuropsychiatry 2001; 6(3): 205–16PubMedCrossRefGoogle Scholar
  29. 29.
    Brand M, Kalbe E, Labudda K, et al. Decision-making impairments in patients with pathological gambling. Psychiatry Res 2005; 133: 91–9PubMedCrossRefGoogle Scholar
  30. 30.
    Kertzman S, Lowengrub K, Aizer A, et al. Stroop performance in pathological gamblers. Psychiatry Res 2006; 142(1): 1–10PubMedCrossRefGoogle Scholar
  31. 31.
    Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160(11): 1990–4PubMedCrossRefGoogle Scholar
  32. 32.
    Cavedini P, Riboldi G, Keller R, et al. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry 2002; 51(4): 334–41PubMedCrossRefGoogle Scholar
  33. 33.
    Soubrie P. Serotonergic neurons and behaviour [in French]. J Pharmacol 1986; 17(2): 107–12PubMedGoogle Scholar
  34. 34.
    Zald DH, Boileau I, El-Dearedy W, et al. Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 2004; 24(17): 4105–12PubMedCrossRefGoogle Scholar
  35. 35.
    Nordin C, Eklundh T. Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr 1999; 4: 25–33PubMedGoogle Scholar
  36. 36.
    Carrasco JL, Saiz-Ruiz J, Hollander E, et al. Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand 1994; 90(6): 427–31PubMedCrossRefGoogle Scholar
  37. 37.
    Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling behavior. Hum Psychopharmacol 1991; 6: S9–12CrossRefGoogle Scholar
  38. 38.
    DeCaria CM, Begaz T, Holander E. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr 1998; 3: 38–47Google Scholar
  39. 39.
    Roy A, DeJong J, Ferraro T, et al. CSF GABA and neuropeptides in pathological gamblers and normal controls. Psychiatry Res 1989; 30(2): 137–44PubMedCrossRefGoogle Scholar
  40. 40.
    Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. J Gambl Stud 2003; 19(1): 85–109PubMedCrossRefGoogle Scholar
  41. 41.
    Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999; 375(1–3): 13–30PubMedCrossRefGoogle Scholar
  42. 42.
    Black KJ, Friedman JH. Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 2006; 67(7): 1118–9PubMedCrossRefGoogle Scholar
  43. 43.
    Grant JE, Williams KA, Kim SW. Update on pathological gambling. Curr Psychiatry Rep 2006; 8(1): 53–8PubMedCrossRefGoogle Scholar
  44. 44.
    Koran LM, Bullock KD, Hartston HJ. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry 2002; 63(8): 704–8PubMedCrossRefGoogle Scholar
  45. 45.
    Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47(9): 813–7PubMedCrossRefGoogle Scholar
  46. 46.
    Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14(1): 9–15PubMedGoogle Scholar
  47. 47.
    Kim SW, Grant JE, Adson DE, et al. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(6): 501–7PubMedCrossRefGoogle Scholar
  48. 48.
    Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003; 18(4): 243–9PubMedCrossRefGoogle Scholar
  49. 49.
    Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66(1): 28–33PubMedCrossRefGoogle Scholar
  50. 50.
    Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006; 21(4): 203–9PubMedCrossRefGoogle Scholar
  51. 51.
    Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(1): 44–8PubMedCrossRefGoogle Scholar
  52. 52.
    Pallanti S, Baldini Rossi N, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry 2002; 63(11): 1034–9PubMedCrossRefGoogle Scholar
  53. 53.
    Coccaro EF, Kavoussi RJ, Sheline YI, et al. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53(6): 531–6PubMedCrossRefGoogle Scholar
  54. 54.
    Hollister LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 1977; 2(3): 203–9PubMedCrossRefGoogle Scholar
  55. 55.
    Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 2001; 62Suppl. 20: 11–7PubMedGoogle Scholar
  56. 56.
    Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001; 16(5): 285–9PubMedCrossRefGoogle Scholar
  57. 57.
    Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49(11): 914–21PubMedCrossRefGoogle Scholar
  58. 58.
    Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163(2): 303–12PubMedCrossRefGoogle Scholar
  59. 59.
    Zwar N, Richmond R. Bupropion sustained release: a therapeutic review of Zyban. Aus Fam Physician 2002; 31: 443–7Google Scholar
  60. 60.
    Gelenberg AJ, Bassuk EL, editors. The practitioner’s guide to psychoactive drugs. 4th ed. New York: Plenum, 1997CrossRefGoogle Scholar
  61. 61.
    Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud 2003; 19(1): 23–51PubMedCrossRefGoogle Scholar
  62. 62.
    Tardieu S, Poirier Y, Micallef J, et al. Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. Acta Psychiatr Scand 2004; 109(1): 75–7, discussion 77-8PubMedCrossRefGoogle Scholar
  63. 63.
    Black D. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacology 2004; 24(1): 108–9CrossRefGoogle Scholar
  64. 64.
    Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol 2005; 25(6): 593–6PubMedCrossRefGoogle Scholar
  65. 65.
    Dannon PN, Lowengrub K, Musin E, et al. Sustained release bupropion in the treatment of SSRI nonresponder pathological gamblers: pilot study and review of the literature. Therapy 2005; 2(5): 753–9CrossRefGoogle Scholar
  66. 66.
    Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63(7): 559–65PubMedCrossRefGoogle Scholar
  67. 67.
    Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162(1): 137–45PubMedCrossRefGoogle Scholar
  68. 68.
    Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007; 67(15): 2231–56PubMedCrossRefGoogle Scholar
  69. 69.
    McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2): 255–61PubMedCrossRefGoogle Scholar
  70. 70.
    Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003; 26(1): 1–4PubMedCrossRefGoogle Scholar
  71. 71.
    Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28(1): 6–10PubMedCrossRefGoogle Scholar
  72. 72.
    Sylvain C, Ladoucuer R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997; 65(5): 727–32PubMedCrossRefGoogle Scholar
  73. 73.
    Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling. Behav Cogn Psychother 1996; 24: 51–72CrossRefGoogle Scholar
  74. 74.
    Echeburua E, Fernandez-Montalvo J, Baez C. Prevention in the treatment of slot-machine pathological gambling: long-term outcome. Behavior Therapy 2000; 31: 351–64CrossRefGoogle Scholar
  75. 75.
    Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol 2006; 74(3): 555–67PubMedCrossRefGoogle Scholar
  76. 76.
    McCusker CG. Cognitive biases and addiction: an evolution in theory and method. Addiction 2001; 96(1): 47–56PubMedCrossRefGoogle Scholar
  77. 77.
    Toneatto T. Cognitive psychopathology of problem gambling. Subst Use Misuse 1999; 34(11): 1593–604PubMedCrossRefGoogle Scholar
  78. 78.
    Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: a cognitive approach. Behav Res Ther 2003; 41(5): 587–96PubMedCrossRefGoogle Scholar
  79. 79.
    Toneatto T, Ladoceur R. Treatment of pathological gambling: a critical review of the literature. Psychol Addict Behav 2003; 17(4): 284–92PubMedCrossRefGoogle Scholar
  80. 80.
    Kausch O, Rugle L, Rowland DY. Lifetime histories of trauma among pathological gamblers. Am J Addict 2006; 15(1): 35–43PubMedCrossRefGoogle Scholar
  81. 81.
    Waska R. Addictions and the quest to control the object. Am J Psychoanal 2006; 66(1): 43–62PubMedCrossRefGoogle Scholar
  82. 82.
    Goudriaan AE, Oosterlaan J, de Beurs E, et al. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction 2006; 101(4): 534–47PubMedCrossRefGoogle Scholar
  83. 83.
    Ravindran AV, Telner J, Bhatla R, et al. Pathological gambling: treatment correlates. Eur Neuropsychopharmacol 2006; 16Suppl. 4: 20Google Scholar
  84. 84.
    Dannon PN, Lowengrub K, Sasson M, et al. Comorbid psychiatric diagnoses in kleptomania and pathological gambling: a preliminary comparison study. Eur Psychiatry 2004; 19(5): 299–302PubMedCrossRefGoogle Scholar
  85. 85.
    Dannon PN, Lowengrub K, Mester R, et al. Pathological gambling: comorbid psychiatric diagnoses in patients and their families. Israeli J Psychiatry 2006; 43(2): 88–92Google Scholar
  86. 86.
    Dannon PN, Lowengrub K, Shagi B, et al. Dual psychiatric diagnoses and substance abuse in pathological gamblers: a preliminary gender comparison study. J Addict Disord 2006; 25(3): 49–54CrossRefGoogle Scholar
  87. 87.
    Grant JE, Kim SW. Comorbidity of impulse control disorders in pathological gamblers. Acta Psychiatr Scand 2003; 108(3): 203–7PubMedCrossRefGoogle Scholar
  88. 88.
    Lynch WJ, Maciejewski PK, Potenza MN. Psychiatric correlates of gambling in adolescents and young adults grouped by age at gambling onset. Arch Gen Psychiatry 2004; 61(11): 1116–22PubMedCrossRefGoogle Scholar
  89. 89.
    Vachon J, Vitaro F, Wanner B, et al. Adolescent gambling: relationships with parent gambling and parenting practices. Psychol Addict Behav 2004; 18(4): 398–401PubMedCrossRefGoogle Scholar
  90. 90.
    Kvale G, Holsten F. Outcome of pharmacological treatments of pathological gambling meta-analysis. J Clin Psychopharmacol 2007; 27(4): 357–64PubMedCrossRefGoogle Scholar
  91. 91.
    Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62Suppl. 20: 26–31PubMedGoogle Scholar
  92. 92.
    Blanco C, Hasin DS, Petry N, et al. Sex differences in subclinical and DSM-IV pathological gambling: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2006; 36(7): 943–53PubMedCrossRefGoogle Scholar
  93. 93.
    Desai RA, Maciejewski PK, Pantalon MV, et al. Gender differences in adolescent gambling. Ann Clin Psychiatry 2005; 17(4): 249–58PubMedCrossRefGoogle Scholar
  94. 94.
    Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56Suppl. 4: 3–6, discussion 53-5PubMedGoogle Scholar
  95. 95.
    Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004; 9(11): 808–16, 818-21PubMedGoogle Scholar
  96. 96.
    Potenza MN, Fiellin DA, Heninger GR, et al. Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 2002; 17(9): 721–32PubMedCrossRefGoogle Scholar
  97. 97.
    Petry NM. How treatments for pathological gambling can be informed by treatments for substance use disorders. Exp Clin Psychopharmacol 2002; 10(3): 184–92PubMedCrossRefGoogle Scholar
  98. 98.
    Kim SW, Grant JE, Yoon G, et al. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol 2006; 29(2): 77–9PubMedCrossRefGoogle Scholar
  99. 99.
    Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two US national surveys. Am J Psychiatry 2006; 163(2): 297–302PubMedCrossRefGoogle Scholar
  100. 100.
    Weite JW, Wieczorek WF, Barnes GM, et al. The relationship of ecological and geographic factors to gambling behavior and pathology. J Gambl Stud 2004; 20(4): 405–10CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Iulian Iancu
    • 1
    • 2
  • Katherine Lowengrub
    • 1
    • 3
  • Yael Dembinsky
    • 1
    • 2
  • Moshe Kotler
    • 1
    • 2
    • 3
  • Pinhas N. Dannon
    • 1
    • 2
    • 3
  1. 1.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Psychiatry B. Department, Beer Yaakov Mental Health CenterTel Aviv UniversityTel AvivIsrael
  3. 3.The Rehovot Community Mental Health & Rehabilitation Clinic (affiliated to Ness Ziona - Beer Yaakov Medical Complex)RehovotIsrael

Personalised recommendations